AUPH Q4 2025 Earnings — Aurinia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

AUPHAurinia Pharmaceuticals Inc.

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$77M+28.8% YoY

Gross Profit

$69M89.0% margin

Operating Income

$33M43.1% margin

Net Income

$211M273.4% margin

EPS (Diluted)

$1.53

QoQ Revenue Growth

+5.0%

Cash Flow

Operating Cash Flow

$45M

Free Cash Flow

$45M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$752M

Total Liabilities

$170M

Stockholders' Equity

$581M

Cash & Equivalents

$80M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$77M	$60M	+28.8%
Gross Profit	$69M	$54M	+26.4%
Operating Income	$33M	-$2M	+2091.6%
Net Income	$211M	$1M	+14651.2%

Revenue Segments

Product

$74M96%

License, Collaboration and Royalty Revenue

$3M4%